Research Analysts Set Expectations for TCRX Q2 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX - Free Report) - Investment analysts at HC Wainwright upped their Q2 2025 earnings per share estimates for TScan Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.29) per share for the quarter, up from their previous estimate of ($0.32). HC Wainwright has a "Buy" rating and a $10.00 price objective on the stock. The consensus estimate for TScan Therapeutics' current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics' Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.18) EPS, FY2026 earnings at ($1.15) EPS, FY2027 earnings at ($0.77) EPS and FY2028 earnings at ($0.31) EPS.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The business had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.62 million.

Several other brokerages have also recently weighed in on TCRX. Wedbush reiterated an "outperform" rating and issued a $7.00 price target on shares of TScan Therapeutics in a research report on Tuesday, May 6th. Morgan Stanley reiterated an "overweight" rating and set a $10.00 price target on shares of TScan Therapeutics in a report on Friday, March 14th. Barclays cut their price target on shares of TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $9.00 target price on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $8.50.

TScan Therapeutics Stock Performance

TCRX traded down $0.04 during trading on Monday, hitting $1.33. 221,396 shares of the company traded hands, compared to its average volume of 362,578. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. The stock's fifty day moving average is $1.48 and its 200 day moving average is $2.66. TScan Therapeutics has a one year low of $1.02 and a one year high of $9.69. The firm has a market cap of $75.27 million, a P/E ratio of -1.25 and a beta of 1.06.

Hedge Funds Weigh In On TScan Therapeutics

A number of hedge funds have recently bought and sold shares of TCRX. Lynx1 Capital Management LP raised its holdings in TScan Therapeutics by 2.5% in the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company's stock worth $16,286,000 after acquiring an additional 132,747 shares during the last quarter. Aberdeen Group plc increased its holdings in TScan Therapeutics by 0.9% in the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company's stock worth $1,230,000 after buying an additional 7,744 shares in the last quarter. abrdn plc raised its position in TScan Therapeutics by 137.8% in the 4th quarter. abrdn plc now owns 883,704 shares of the company's stock worth $2,686,000 after buying an additional 512,049 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in TScan Therapeutics by 108.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company's stock valued at $851,000 after acquiring an additional 145,731 shares during the period. Finally, Tocqueville Asset Management L.P. grew its stake in shares of TScan Therapeutics by 26.8% in the fourth quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company's stock worth $793,000 after acquiring an additional 55,140 shares during the period. Institutional investors own 82.83% of the company's stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.